Fabric Genomics provides an AI-powered software platform and clinical services to accelerate and scale the interpretation of genomic data for diagnostic use. Its technology, which boasts high accuracy and automation, is used by leading hospitals and genomics programs, particularly in pediatric and neonatal intensive care settings. In late 2024, the company was acquired by GeneDx, a move aimed at expanding decentralized, AI-powered genetic testing at a global scale. This acquisition marks a significant transition, integrating Fabric's software expertise into a larger diagnostic services entity.
AI-driven cloud software for automated variant calling, ACMG classification, and clinical report generation from whole genome, exome, and panel sequencing data.
Funding History
3
Total raised:$75M
Series C$40MRoche
Series B$25MCelgene
Series A$10MCelgene
Opportunities
The acquisition by GeneDx provides a direct channel to scale its AI technology across a large, commercial diagnostic laboratory, accelerating market penetration.
Growing demand for rapid whole-genome sequencing in acute care and population-scale newborn screening programs presents significant expansion avenues for its automated interpretation platform.
Risk Factors
Intense competition from other AI genomics software providers and in-house bioinformatics solutions threatens market share.
Post-acquisition integration risks include technological harmonization and cultural alignment, which could disrupt operations or slow innovation if not managed effectively.
Competitive Landscape
Fabric competes in the clinical genomics interpretation software market against companies like Sophia Genetics, DNAnexus, PierianDx, and Qiagen, as well as the in-house solutions of large sequencing service providers. Its differentiation hinges on its explainable AI, high claimed accuracy, and proven deployments in leading pediatric hospitals.
